| Symbol | PXMTF |
|---|---|
| Name | PHAXIAM THERAPEUTICS S.A |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 69008 France 60 Avenue Rockefeller, Batiment Adenine, |
| Telephone | +33 4 78 74 44 38 |
| Fax | — |
| — | |
| Website | https://erytech.com/ |
| Incorporation | FR |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001624422 |
| Description | PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. Additional info from OTC: |
No news found.